Found vs MEDVi: Which Is Cheaper?
Both programmes priced at a standard therapeutic dose, with the subtraction shown for each molecule separately.
Which is cheaper: the arithmetic
Standard therapeutic dosing only, at the lowest verified rate each programme publishes. Each molecule is answered separately, because the two are priced differently at the same provider and one answer to “which is cheaper” would be answering an incomplete question.
Tirzepatide: Found at $169 a month against MEDVi at $399. $399 − $169 = $230 a month, or $2,760 across a year — a 58% difference. Found is cheaper on tirzepatide. That rate requires a twelve-month commitment, roughly $2,028 paid up front, and compounded medication is generally not refundable once shipped.
Semaglutide: Found at $169 a month against MEDVi at $299. $299 − $169 = $130 a month, or $1,560 across a year — a 43% difference. Found is cheaper on semaglutide. That rate requires a twelve-month commitment, roughly $2,028 paid up front, and compounded medication is generally not refundable once shipped.
Figures come from our published dataset, captured 2026-08-08. Microdose tiers are excluded: they sit below every dose the pivotal trials studied and are not a cheaper route to the same result.
What the price does not tell you
Whether the dispensing pharmacy is named before purchase, which is the only verification available to you before money changes hands. What the cancellation terms are, and what is refundable once medication has shipped. Whether laboratory work is required and billed separately. And whether a clinician licensed in your state is available, which decides whether the programme can serve you at all.
Full profiles: Found and MEDVi. Complete rankings at the semaglutide and tirzepatide comparison tables.
Compounded GLP-1 medicines are not FDA-approved and are not therapeutically equivalent to any brand-name product. This is consumer price research, not medical advice.
The numbers behind this page
Checking the figures in this comparison
Every price quoted in this comparison comes from the programme's own pricing page and carries the date it was captured. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
The figures in this comparison sit inside a market with a measurable shape, and that shape is what makes any single price readable.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $133 to $299 across 12 programmes; tirzepatide $169 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Where this sits in the market
The figures in this comparison sit inside a market with a measurable shape, and that shape is what makes any single price readable.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $133 to $299 across 12 programmes; tirzepatide $169 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Questions this page answers
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
Oak Longevity at $133 a month for semaglutide and Found at $169 for tirzepatide, both at standard therapeutic dosing.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.